Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Tech Talks Daily

Tech Talks Daily artwork

Could Disease Chemistry Help Treat the Brain With Enabled Therapeutics

Aug 14, 202627 minAudio

What if the chemistry created by neurological disease could help activate medicine precisely where it is needed? In this episode of Tech Talks Daily, I speak with Sara Isbell, neuroscientist and co-founder of Enabled Therapeutics, about a proposed approach to one of medicine's most stubborn problems: delivering effective drugs to diseased brain tissue without exposing healthy areas to the same activity. Sara explains how the blood-brain barrier prevents many promising compounds from reaching the brain. When drugs do enter, they may spread across healthy and diseased regions alike, creating a difficult balance between therapeutic benefit and unwanted effects. We hear how an unexpected laboratory result led Sara and her co-founder to investigate whether pathological oxidative stress could convert a precursor molecule into a biologically active compound near the affected tissue. Sara describes this as pathology-gated therapeutic activation, where disease-associated chemistry provides the trigger that turns the medicine on. This remains developing science. At the time of recording, Enabled Therapeutics was preparing its first peer-reviewed manuscript and seeking partners to support further studies. Sara explains why reproducible evidence, regulatory guidance, and careful laboratory validation must determine whether the hypothesis advances. We also discuss how AI helps small biotechnology teams review literature, organize regulatory materials, connect ideas across scientific disciplines, and identify possible hypotheses. However, Sara offers an important reminder: AI can propose possibilities, but nature and experimental evidence decide what is true. Could following one unexpected result eventually offer researchers another way to approach neurological disease? Listen to the conversation and share your thoughts with me.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. IGEL Reaches Unicorn Status and Why Endpoint Resilience Matters Now

    Nov 20, 202624 minAudio

    What does IGEL reaching unicorn status mean for the customers and people behind the company? It was lovely to welcome my friend Klaus back to Tech Talks Daily for a conversation that felt like a catch-up with some...

    Credit the people on this episode

  2. How to Verify AI Research Before Acting with AlphaSense

    Nov 19, 202625 minAudio

    Would you put an AI answer in front of your board if you couldn't tell which source supported its most important claim? On Tech Talks Daily, I'm joined by Julia Lecocq, who leads corporate sales in Europe and...

    Credit the people on this episode

  3. From Security Alert to Verified Fix with Cogent Security

    Nov 18, 202619 minAudio

    How much time passes between discovering a vulnerability and getting the right person to fix it? On Tech Talks Daily, I'm joined by Vineet Edupuganti, co-founder and CEO of Cogent Security, to talk about the work that...

    Credit the people on this episode

  4. Measuring the True Cost of AI With Front

    Nov 17, 202623 minAudio

    What does AI really cost when a cheap model fails, retries the task, hands the work to a person, and leaves the customer returning with the same problem? In this episode of Tech Talks Daily, I welcome back Dan...

    Credit the people on this episode

  5. Making Time For Real Work With AI and lilAgents

    Nov 17, 202637 minAudio

    When AI saves you time, who gets to decide what happens to the time you get back? On Tech Talks Daily, I welcome back David V. Kimball, co-founder and CEO of lilAgents. David started working remotely in 2018, after most...

    Credit the people on this episode